Comprehensive Investigation into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ubiquitin-conjugating enzyme E2S (UBE2S) plays roles in protein degradation and signal transduction.
• The specific function of UBE2S in melanoma development remains largely undefined.
• UBE2S overexpression is observed in malignant melanoma tissues and correlates with advanced tumor staging.

Purpose of the Study:

• To investigate the role of UBE2S in melanoma development using in vitro and in vivo models.
• To elucidate the molecular mechanisms by which UBE2S influences melanoma progression.

Main Methods:

• Designed UBE2S short hairpin RNA (shUBE2S) for lentiviral transfection into melanoma cell lines (A375, SK-MEL-28, MUM-2B).
• Performed whole-genome gene expression analysis to identify differentially regulated genes post-shUBE2S treatment.
• Assessed melanoma cell proliferation, apoptosis, cell cycle, epithelial-to-mesenchymal transition (EMT) markers, and tumor growth in vivo in BALB/C nude mice.

Main Results:

• shUBE2S treatment led to significant upregulation and downregulation of genes involved in immune reactions, apoptosis, DNA damage repair, and cell movement.
• Melanoma cell proliferation was inhibited, apoptosis was increased, and cell cycle arrest occurred at the G1/S phase.
• Expression of EMT-related proteins was suppressed, and tumor growth was significantly reduced in vivo.

Conclusions:

• UBE2S promotes melanoma development by influencing cell proliferation, apoptosis, cell cycle progression, EMT, and immune responses.
• shUBE2S treatment offers a potential therapeutic strategy by inducing G1/S phase arrest, inhibiting proliferation, promoting apoptosis, and suppressing tumor growth.
• These findings highlight UBE2S as a potential therapeutic target for melanoma and warrant further clinical investigation.